These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36057616)

  • 41. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
    Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
    Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using the ATN system as a guide for the neuropsychological assessment of Alzheimer's disease.
    Florean I; Penolazzi B; Menichelli A; Pastore M; Cattaruzza T; Mazzon G; Manganotti P
    J Clin Exp Neuropsychol; 2021 Nov; 43(9):926-943. PubMed ID: 35166171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.
    Biel D; Brendel M; Rubinski A; Buerger K; Janowitz D; Dichgans M; Franzmeier N;
    Alzheimers Res Ther; 2021 Aug; 13(1):137. PubMed ID: 34384484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regional [
    Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
    Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
    Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.
    Soldan A; Pettigrew C; Fagan AM; Schindler SE; Moghekar A; Fowler C; Li QX; Collins SJ; Carlsson C; Asthana S; Masters CL; Johnson S; Morris JC; Albert M; Gross AL
    Neurology; 2019 Apr; 92(14):e1567-e1579. PubMed ID: 30842300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
    Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
    Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.
    Dubbelman MA; Hendriksen HMA; Harrison JE; Vijverberg EGB; Prins ND; Kroeze LA; Ottenhoff L; Van Leeuwenstijn MMSSA; Verberk IMW; Teunissen CE; van de Giessen EM; Van Harten AC; Van Der Flier WM; Sikkes SAM
    Neurology; 2024 Jan; 102(2):e207978. PubMed ID: 38165338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.
    Düzel E; Ziegler G; Berron D; Maass A; Schütze H; Cardenas-Blanco A; Glanz W; Metzger C; Dobisch L; Reuter M; Spottke A; Brosseron F; Fliessbach K; Heneka MT; Laske C; Peters O; Priller J; Spruth EJ; Ramirez A; Speck O; Schneider A; Teipel S; Kilimann I; Jens W; Schott BH; Preis L; Gref D; Maier F; Munk MH; Roy N; Ballarini T; Yakupov R; Haynes JD; Dechent P; Scheffler K; Wagner M; Jessen F
    Brain; 2022 May; 145(4):1473-1485. PubMed ID: 35352105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.
    Canu E; Rugarli G; Coraglia F; Basaia S; Cecchetti G; Calloni SF; Vezzulli PQ; Spinelli EG; Santangelo R; Caso F; Falini A; Magnani G; Filippi M; Agosta F
    J Neurol; 2024 May; 271(5):2716-2729. PubMed ID: 38381175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.
    Kim H; Levine A; Cohen D; Gehrman P; Zhu X; Devanand DP; Lee S; Goldberg TE;
    J Alzheimers Dis; 2022; 87(4):1567-1580. PubMed ID: 35491776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals.
    Ebenau JL; Visser D; Verfaillie SCJ; Timmers T; van Leeuwenstijn MSSA; Kate MT; Windhorst AD; Barkhof F; Scheltens P; Prins ND; Boellaard R; van der Flier WM; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):410-422. PubMed ID: 36071221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
    Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
    Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints.
    Lu J; Ma X; Zhang H; Xiao Z; Li M; Wu J; Ju Z; Chen L; Zheng L; Ge J; Liang X; Bao W; Wu P; Ding D; Yen TC; Guan Y; Zuo C; Zhao Q;
    Transl Neurodegener; 2023 Jun; 12(1):34. PubMed ID: 37381042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.